Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05714839
Title A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)
Acronym DREAMM-20
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR | AUS

Facility Status City State Zip Country Details
GSK Investigational Site RECRUITING Ciudadela Buenos Aires B1702 Argentina Details
GSK Investigational Site RECRUITING Fitzroy Victoria 3065 Australia Details
GSK Investigational Site RECRUITING Nedlands Western Australia 6009 Australia Details
GSK Investigational Site RECRUITING Salvador Bahía 41253-190 Brazil Details
GSK Investigational Site RECRUITING São Paulo 04537-080 Brazil Details
GSK Investigational Site RECRUITING Aomori 030-8553 Japan Details
GSK Investigational Site RECRUITING Osaka 545-8586 Japan Details
GSK Investigational Site RECRUITING Seoul, Korea 137-701 Korea, Republic of Details
GSK Investigational Site RECRUITING Seoul 138-736 Korea, Republic of Details
GSK Investigational Site RECRUITING Mexico City 01330 Mexico Details
GSK Investigational Site RECRUITING Gdansk 80-214 Poland Details
GSK Investigational Site RECRUITING Lublin 20-081 Poland Details
GSK Investigational Site RECRUITING Changhua 500 Taiwan Details
GSK Investigational Site RECRUITING Taipei 100 Taiwan Details
GSK Investigational Site RECRUITING Kayseri 38039 Turkey Details
GSK Investigational Site RECRUITING Leicester LE1 5WW United Kingdom Details
GSK Investigational Site RECRUITING Oxford. OX3 7LE United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field